A steady stream of dealmaking in recent years, primarily small, in-licensing transactions to build pipeline and portfolio, transformed Forest under the leadership of longtime CEO Howard Solomon. The activity was driven in large part by the anticipated, huge 2012 patent cliff, but it was far from enough.

A steady stream of deal-making in recent years, primarily small, in-licensing transactions to build pipeline and portfolio, transformed Forest under the leadership of longtime CEO Howard Solomon. The activity was driven in large part by the anticipated, huge 2012 patent cliff, but it was far from enough.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

The founders of Small Bone Innovations believes the device industry is entering the decade of small bones and joints, and has embarked on a consolidation strategy to prepare for dramatic innovation and change in what today is a fragmented marketplace.